USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
Synedgen, Inc
Address:
1420 N. Claremont Blvd
Suite 105D
Claremont, CA 91711-
Phone:
N/A
URL:
EIN:
800384893
DUNS:
830276353
Number of Employees:
10
Woman-Owned?:
Yes
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $499,108.00 4
SBIR Phase II $2,834,356.00 2

Award List:

Prevention and Treatment of Oral Biofilms and Related Oral Disease by Soluble Chi

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$99,665.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): A need remains for safe and effective, prophylactic and therapeutic treatments for controlling bacterial populations in dental plaque and treating periodontal disease. We have developed derivatives of natural biopolyme rs that have demonstrable effectiveness in… More

Wound Decontamination for the Prevention and Treatment of Multi-drug Resistant Ba

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$99,638.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): The frequency of multi-drug resistant infections is increasing at an alarming rate. Equally concerning is the limited therapeutic options available for effective treatment, resulting in increased morbidity and mortality associated with these highly resistant… More

Antimicrobial and Regenerative Treatment for Oral Mucositis

Award Year / Program / Phase:
2011 / SBIR / Phase II
Award Amount:
$1,963,826.00
Agency:
HHS
Principal Investigator:
Shenda Baker – 909-447-6858
Abstract:
DESCRIPTION (provided by applicant): Oral mucositis is a frequent and painful complication of chemotherapy, radiotherapy and immune compromise. Mucositis is associated with significant morbidity including pain, oral lesions, dehydration and nutritional compromise including limiting calorie intake… More

Effective New Topical Treatment to Reduce Scar Formation in Burns

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$149,904.00
Agency:
DOD
Principal Investigator:
Shenda Baker, President – (909) 447-6858
Abstract:
Thermal injury is common in military conflicts due to primarily to the widespread use of explosive devices. Burns can produce scars that are excessive, physically debilitating and functionally damaging. There is a critical need for an effective product that can control bacterial contamination and… More

Rectal Medication Administration Device for Palliative Care

Award Year / Program / Phase:
2013 / SBIR / Phase I
Award Amount:
$149,901.00
Agency:
HHS
Principal Investigator:
Shenda Baker – 909-447-6858
Abstract:
DESCRIPTION (provided by applicant): Thick hyperviscous mucus and delayed mucociliary clearance are important elements underlying cystic fibrosis (CF) pathogenesis, but currently available therapeutics exhibit limited efficacy to combat mucus stasis. In addition, biofilms that populate the CF lung… More

Effective New Topical Treatment to Reduce Scar Formation in Burns

Award Year / Program / Phase:
2014 / SBIR / Phase II
Award Amount:
$870,530.00
Agency / Branch:
DOD / DHP
Principal Investigator:
Shenda Baker, President and COO – (909) 447-6858
Abstract:
Thermal injury is common in military conflicts due primarily to the widespread use of explosive devices. Though scar formation is a natural process of wound healing, burns can produce scars that are excessive, physically debilitating and functionally damaging. Synedgen has demonstrated the efficacy… More